BYLieve (CBYL719X402)

A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

Ouvert à Saint-Cloud depuis le : 13/11/2017
Public cible : Adult
Phase : Phase II

Description de l'essai

The purpose of this studis to assess the efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant

Url of the trial

Investigateur principal

FLORENCE LEREBOURS

Médecin

Contacter